Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents

Clinical Biochemistry

Volumn 42, Issue 10-11, 2009, Pages 984-990

  Belo, Vanessa A ^a   Souza Costa, Debora C ^b   Lana, Carla M ^b   Caputo, Fabio L D ^b   Marcaccini, Andrea M ^c   Gerlach, Raquel F ^c   Bastos, Marcus G ^b   Tanus Santos, Jose E ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adolescents; Children; Metalloproteinases; Obesity; TIMPs

Indexed keywords

GELATINASE A; GELATINASE B; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CARDIOVASCULAR RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD; ZYMOGRAPHY;

ADOLESCENT; CHILD; DEMOGRAPHY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; OBESITY; PROTEIN PRECURSORS; SEX CHARACTERISTICS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 67349277709     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.03.025     Document Type: Article

References (42)

1. James P.T., Rigby N., and Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur. J. Cardiovasc. Prev. Rehabil. 11 (2004) 3-8
2. Chinn S., and Rona R.J. Prevalence and trends in overweight and obesity in three cross sectional studies of British Children, 1974-94. BMJ 322 (2001) 24-26
3. Adams K.F., Schatzkin A., Harris T.B., Kipnis V., Mouw T., Ballard-Barbash R., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N. Engl. J. Med. 355 (2006) 763-778
4. Van Gaal L.F., Mertens I.L., and De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880
5. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
6. Beaudeux J.L., Giral P., Bruckert E., Foglietti M.J., and Chapman M.J. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin. Chem. Lab. Med. 42 (2004) 121-131
7. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90 (2002) 251-262
8. Palei A.C., Sandrim V.C., Cavalli R.C., and Tanus-Santos J.E. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin. Biochem. 41 (2008) 875-880
9. Castro M.M., Rizzi E., Figueiredo-Lopes L., Fernandes K., Bendhack L.M., Pitol D.L., et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198 (2008) 320-331
10. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
11. Kato R., Momiyama Y., Ohmori R., Taniguchi H., Nakamura H., and Ohsuzu F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ. J. 69 (2005) 1035-1040
12. Turu M.M., Krupinski J., Catena E., Rosell A., Montaner J., Rubio F., et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 187 (2006) 161-169
13. Glowinska-Olszewska B., and Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 56 (2007) 799-805
14. Glowinska-Olszewska B., Urban M., and Florys B. Selected matrix metalloproteinases (MMP-2, MMP-9) in obese children and adolescents. Endokrynol. Diabetol. Chor. Przemiany Materii Wieku Rozw 12 (2006) 179-183
15. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., and Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem. 267 (1992) 4583-4591
16. Tuomainen A.M., Nyyssonen K., Laukkanen J.A., Tervahartiala T., Tuomainen T.P., Salonen J.T., et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2722-2728
17. Berenson G.S., Srinivasan S.R., Bao W., Newman III W.P., Tracy R.E., and Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 338 (1998) 1650-1656
18. Kuczmarski R.J., Ogden C.L., Grummer-Strawn L.M., Flegal K.M., Guo S.S., Wei R., et al. CDC growth charts: United States. Adv. Data (2000) 1-27
19. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 98 (1996) 649-658
20. Martinez M.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B., Gerlach R.F., et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. Cardiovasc. Pharmacol. 47 (2006) 117-122
21. Souza-Costa D.C., Sandrim V.C., Lopes L.F., Gerlach R.F., Rego E.M., and Tanus-Santos J.E. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193 (2007) 438-444
22. Martinez M.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B., Gerlach R.F., et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. Cardiovasc. Pharmacol. 47 (2006) 117-122
23. Demacq C., de Souza A.P., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin. Chim. Acta 365 (2006) 183-187
24. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem. 40 (2007) 119-123
25. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., and Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal. Biochem. 344 (2005) 147-149
26. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin. Biochem. 38 (2005) 410-414
27. Makowski G.S., and Ramsby M.L. Identification and partial characterization of three calcium- and zinc-independent gelatinases constitutively present in human circulation. Biochem. Mol. Biol. Int. 46 (1998) 1043-1053
28. Herman M.P., Sukhova G.K., Libby P., Gerdes N., Tang N., Horton D.B., et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 104 (2001) 1899-1904
29. Koh K.K., Han S.H., and Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J. Am. Coll. Cardiol. 46 (2005) 1978-1985
30. Aquilante C.L., Beitelshees A.L., and Zineh I. Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin. Chim. Acta 379 (2007) 48-52
31. Tayebjee M.H., Nadar S., Blann A.D., Gareth Beevers D., MacFadyen R.J., and Lip G.Y. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am. J. Hypertens. 17 (2004) 764-769
32. Tayebjee M.H., Nadar S.K., MacFadyen R.J., and Lip G.Y. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension relationship to tissue Doppler indices of diastolic relaxation. Am. J. Hypertens 17 (2004) 770-774
33. Derosa G., Ferrari I., D'Angelo A., Tinelli C., Salvadeo S.A., Ciccarelli L., et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 15 (2008) 219-224
34. Valle M., Martos R., Gascon F., Canete R., Zafra M.A., and Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab. 31 (2005) 55-62
35. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86 (2001) 1930-1935
36. Stefan N., Bunt J.C., Salbe A.D., Funahashi T., Matsuzawa Y., and Tataranni P.A. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J. Clin. Endocrinol. Metab. 87 (2002) 4652-4656
37. Reinehr T., Roth C., Menke T., and Andler W. Adiponectin before and after weight loss in obese children. J. Clin. Endocrinol. Metab. 89 (2004) 3790-3794
38. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
39. Kumada M., Kihara S., Ouchi N., Kobayashi H., Okamoto Y., Ohashi K., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109 (2004) 2046-2049
40. Glowinska-Olszewska B., Urban M., and Florys B. Selected matrix metalloproteinases (MMP-2, MMP-9) in obese children and adolescents. Endokrynol. Diabetol. Chor Przemiany Materii Wieku Rozw 12 (2006) 179-183
41. Tayebjee M.H., Lip G.Y., Blann A.D., and Macfadyen R.J. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb. Res. 115 (2005) 205-210
42. Goncalves F.M., Jacob-Ferreira A.L., Gomes V.A., Casella-Filho A., Chagas A.C., Marcaccini A.M., et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403 (2009) 173-177